The CAR is pleased to announce our collaboration with Boehringer Ingelheim Canada with a focus on enhancing thoracic treatment through advanced solutions specific to pulmonary health. Boehringer Ingelheim Canada is a leading research-driven biopharmaceutical company that creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Approximately 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.

“We are very pleased to collaborate with Boehringer Ingelheim Canada to improve the health of patients across the country. Pulmonary disease affects thousands of Canadians every year. By integrating innovative solutions and technologies that help to better diagnose and treat patients, we can improve many lives. As the end users of these solutions, radiologists have an important role to play in communicating feedback regarding the impact on patient care. Our industry partnerships allow us the opportunity to provide valuable input into delivery of these systems,” said Dr. Gilles Soulez, CAR President.

Click here to learn more about Boehringer Ingelheim Canada.